U.S. stock futures edged higher Friday, buoyed by generally positive quarterly earnings, as well as healthy economic data.
Here are some of the biggest premarket U.S. stock movers today:

Netflix (NASDAQ:NFLX) stock fell 1.7% after the streaming giant’s second-quarter earnings and outlook were solid, but failed to live up to heightened analyst expectations.

American Express (NYSE:AXP) stock rose 1.8% after the credit card behemoth exceeded estimates for second-quarter profit, fueled by resilient spending by its affluent cardholders.

3M Company (NYSE:MMM) stock rose 2.8% after the industrial giant raised its full-year profit forecast, as cost-cutting measures and efforts to focus on high-margin products are paying off.

Schlumberger (NYSE:SLB) stock rose 0.7% after the oilfield services company posted second-quarter results that were above expectations, boosted by growth at its digital platforms that helped offset lower sales of exploration data.

Norfolk Southern (NYSE:NSC) stock surged 4% after the Wall Street Journal reported that Union Pacific (NYSE:UNP) is in talks to acquire the railway operator.

Interactive Brokers (NASDAQ:IBKR) stock gained 5% after the brokerage firm reported total net interest income for the second quarter that beat the average analyst estimate.

Chevron (NYSE:CVX) stock rose 3.1% after CNBC reported that the oil major has triumphed in a mediation case against rival Exxon (NYSE:XOM) over which company owned the right over certain oilfields in Guyana, allowing Chevron to move forward with its $53 billion acquisition of Hess (NYSE:HES), up 7.2%.

Robinhood Markets (NASDAQ:HOOD) and Coinbase Global (NASDAQ:COIN) both gained after the U.S. House of Representatives passed a bill that would develop a regulatory framework for cryptocurrencies.

Talen Energy (NASDAQ:TLN) stock rose 15% after the power infrastructure company said it will buy two gas-fired power plants located in Pennsylvania and Ohio for $3.5 billion.

Symbotic (NASDAQ:SYM) stock fell 1.7% after Deutsche Bank downgraded its stance on the automation technology company to “hold” from “buy”, saying much of the stock’s growth is already priced in at the current valuation.

Sarepta Therapeutics (NASDAQ:SRPT) stock fell 30% after the company disclosed another patient death linked to its gene therapy programs, this time during an early-stage trial for limb-girdle muscular dystrophy.